drugset / Trial / NCT06396416
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Phase 4
Recruiting
60 enrolled
Western University, Canada
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · collabQueen Elizabeth II Health Sciences Centre · collabUnity Health Toronto · collab
RandomizedParallel-groupDouble-blindOther
Summary
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Timeline
- Start
- 2024-09-26
- Primary completion
- 2026-09-30
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2 mg | Subcutaneous |